Studies in NSCLC (PC-9 cells) and erlotinib-resistant NSCLC (PC-1/ER) cell lines demonstrated that OTUD1 inactivated the SOX9/SPP1 axis by blocking the nuclear translocation and activity of YAP1, which ultimately reversed erlotinib resistance in NSCLC cells [33]. Here, SOX9 is linked to non-small cell lung carcinoma.